ストックスクリーナーアプリを入手
11.72
3.93%
-0.48
アフターアワーズ：
13.70
1.98
+16.89%
Promis Neurosciences Inc (PMN) 最新ニュース
ProMIS Neurosciences Inc (PMN) Income Statement - TradingKey
ProMIS Neurosciences to present interim Alzheimer’s trial data on PMN310 - TipRanks
ProMIS to host webinar on Alzheimer’s trial interim data - Investing.com
Two Alzheimer’s researchers join ProMIS webinar on blinded trial data - Stock Titan
PMN Initiated Coverage by Chardan Capital -- Rating Set to Buy - GuruFocus
PMN|ProMIS Neurosciences Inc|Price:11.655|Chg%:-0.545 - TradingKey
ProMIS Neurosciences Inc (PMN) Balance Sheet - TradingKey
Chardan initiates ProMIS Neurosciences stock with buy rating By Investing.com - Investing.com Canada
PMN|ProMIS Neurosciences Inc|Price:12.200|Chg%:-0.410 - TradingKey
ProMIS Neurosciences Inc (PMN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ProMIS Neurosciences Inc (PMN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ProMIS Neurosciences Inc (PMN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ProMIS Neurosciences Inc (PMN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ProMIS Neurosciences Inc (PMN) Institutional Confidence - TradingKey
ProMIS Neurosciences Inc (PMN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ProMIS Neurosciences Inc (PMN) Cash Flow - TradingKey
ProMIS Neurosciences Inc. Revenue Breakdown – NASDAQ:PMN - TradingView
ProMIS Neurosciences Inc (PMN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Guggenheim Sticks to Their Buy Rating for ProMIS Neurosciences (PMN) - The Globe and Mail
H.C. Wainwright Maintains ProMIS Neurosciences(PMN.US) With Buy Rating, Maintains Target Price $18 - Moomoo
ProMIS reports PMN310 oligomer reduction at 29 days - grafa.com
ProMIS Neurosciences (PMN) Reports Dose-Dependent Reduction in A - GuruFocus
One Dose of PMN310 Reduced Toxic Amyloid Oligomers in Spinal Fluid - Stock Titan
ProMIS Neurosciences Reports Dose-Dependent Reduction of Amyloid-Beta Oligomers for PMN310 in Healthy Volunteers - Quiver Quantitative
ProMIS Neurosciences Reports First Human Evidence of - GlobeNewswire
ProMIS Neurosciences Inc. Financial Statements – NASDAQ:PMN - TradingView
PMN Initiated Coverage by Roth Capital -- Rating Set to Buy - GuruFocus
ProMIS Neurosciences (PMN) Slips Marginally, Holds Near Key SupportTick Index - dars.gov.et
PMN Initiated Coverage by Cantor Fitzgerald -- Rating Set to Ove - GuruFocus
Wall Street Analysts See a 230.23% Upside in Promis Neurosciences (PMN): Can the Stock Really Move This High? - Yahoo Finance
ProMIS Neurosciences Inc (PMN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Enterprise value to revenue forward of ProMIS Neurosciences Inc. – NASDAQ:PMN - TradingView
ProMIS Neurosciences Inc. Actuals & Estimates (NASDAQ:PMN) - TradingView
PMN Forecast — Price Target — Prediction for 2027 - TradingView
Price to earnings forward of ProMIS Neurosciences Inc. – NASDAQ:PMN - TradingView
Price to sales forward of ProMIS Neurosciences Inc. – NASDAQ:PMN - TradingView
Price to book forward of ProMIS Neurosciences Inc. – NASDAQ:PMN - TradingView
PMN Reiterated by HC Wainwright & Co. -- Price Target Maintained at $18 - GuruFocus
H.C. Wainwright reiterates ProMIS Neurosciences stock rating at buy By Investing.com - Investing.com Nigeria
PMN Q1 2026 Earnings: Narrower-Than-Expected Loss as Preclinical Pipeline AdvancesEBITDA Estimate Trend - DonanımHaber
ProMIS Neurosciences Inc (PMN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
PMN Q1 2026 Earnings: EPS Beat Surprises as ProMIS Advances PipelinePretax Income Report - newsline.com
PMN Q1 2026 Earnings: Narrowing Losses Amidst Clinical ProgressProfit Inflection Point - newsline.com
ProMIS Neurosciences (PMN) Dips 3.54% as Biotech Stock Tests Key Support ZonePrice Action Signals - newsline.com
All You Need to Know About Promis Neurosciences (PMN) Rating Upgrade to Buy - Yahoo Finance
Wall Street Analysts Think Promis Neurosciences (PMN) Could Surge 231.78%: Read This Before Placing a Bet - Yahoo Finance
ProMIS Neurosciences Inc. (PMN) Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Cost Discipline Amid Pipeline AdvancesAnalyst Drop Coverage - newsline.com
H.C. Wainwright reiterates Buy on ProMIS Neurosciences stock By Investing.com - Investing.com Canada
1.97%
0.83%
大文字化:
|
ボリューム (24 時間):